EQT Life Sciences sells its minority stake in Tubulis, a Germany-based clinical-stage biotech company specializing in next-generation antibody-drug conjugates (ADCs), to Gilead Sciences for up to **USD 5.0 billion**. The transaction marks the exit of EQT Life Sciences’ investment in Tubulis through its LSP 7 fund. Tubulis focuses on developing innovative ADC therapies, a segment gaining traction in oncology treatments.
EQT Life Sciences leads a **USD 183 million Series C** investment in **Electra Therapeutics**, a late-stage US biotech company. The firm develops precision medicines targeting overactive immune cells in immune-mediated diseases and cancer, aiming to preserve normal immune function. Electra’s approach distinguishes itself by selectively addressing disease-driving immune responses.
EQT Life Sciences leads a **USD 44 million Series B** investment in **Cyted Health**, a gastrointestinal (GI) molecular diagnostics company, to accelerate its U.S. expansion. Advent Life Sciences and British Business Bank co-lead the round, alongside existing investors Morningside and BGF. The funding supports Cyted Health’s growth in molecular diagnostics for gastrointestinal conditions.
EQT Life Sciences finalizes its LSP Dementia Fund, securing **EUR 260 million** in committed capital—exceeding its **EUR 100 million** target. The fund targets investments in companies advancing **neurodegenerative disease therapies**, including drugs and medical technologies. This marks the first close of EQT’s inaugural life sciences-focused fund.
Mar 2023eqtgroup.comNews article
EQT Life Sciences
EQT Life Sciences, formerly LSP, is a life sciences investor targeting therapeutics, medical devices, diagnostics and healthtech companies globally.
